Abramson, Jeremy S <br/><br/>
Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.  [electronic resource] 

 -  Cancer  Sep 2010 
 - 4283-90 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0008-543X 
<br/><br/><label>Standard No.: </label>10.1002/cncr.25278  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--analysis<br/>Central Nervous System Neoplasms--drug therapy<br/>Cyclophosphamide--analysis<br/>Disease-Free Survival<br/>Doxorubicin--analysis<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Injections, Intravenous<br/>Lymphoma, Large B-Cell, Diffuse--drug therapy<br/>Male<br/>Methotrexate--administration & dosage<br/>Middle Aged<br/>Prednisone--analysis<br/>Recurrence<br/>Risk<br/>Rituximab<br/>Vincristine--analysis